Background: The Foundation for the NIH Sarcopenia Project validated cutpoints for appendicular lean mass. We ascertained the relationship between low lean mass (LLM), obesity, and mortality and identified predictors in this subgroup. Methods: A total of 4,984 subjects aged 60 years and older were identified from the National Health and Nutrition Examination Survey 1999-2004 linked to the National Death Index. LLM was defined using reduced appendicular lean mass (men < 19.75 kg; females < 15.02 kg). Obesity was defined using dual-energy x-ray absorptiometry body fat (males ≥ 25%; females ≥ 35%). LLM with obesity was defined using criteria for both LLM and obesity. Proportional hazard models determined mortality risk for LLM and LLM with obesity, separately (referent = no LLM and no LLM with obesity, respectively). Results: Mean age was 71.1 ± 0.19 years (56.5% female). Median follow-up was 102 months (interquartile range: 78, 124) with 1,901 deaths (35.0%). Prevalence of LLM with obesity was 33.5% in females and 12.6% in males. In those with LLM, overall mortality risk was 1.49 (1.27, 1.73) in males and 1.19 (1.02, 1.40) in females. Mortality risk in LLM with obesity was 1.31 (1.11, 1.55) and 0.99 (0.85, 1.16) in males and females, respectively. Age, diabetes, history of stroke, congestive heart failure, cancer, and kidney disease were predictive of death. Conclusions: Risk of death is higher in subjects with LLM than with LLM and obesity. Having advanced age, diabetes, stroke, heart failure, cancer, and renal disease predict a worse prognosis in both classifications.
Sarcopenia, defined as the loss of muscle and function with aging, is a major risk factor for numerous adverse health consequences in older adults (1) . While sarcopenia can be accelerated following an acute illness, a natural loss occurs during the aging process (2) . However, its definition in the past has been fraught with considerable methodological challenges (3), prompting a consortium of experts to work with the Foundation for the National Institutes of Health (FNIH) to identify individuals in clinical practice at risk for clinical weakness using body composition and functional measures (1, 4, 5) . Better characterizing sarcopenia is an essential first step in describing its natural history and long-term outcomes of those with this geriatric syndrome in older adults.
The emergence of the obesity epidemic in older adults potentially compounds the adverse outcomes of individuals with sarcopenia (6) . Adults with obesity surviving to older adulthood are more likely to have declines in physical function (7) , morbidity (8) , and institutionalization (9) . The interplay between sarcopenia and obesity in patients with both syndromes is referred to as sarcopenic obesity and is an area of intense research requiring further attention. Both disorders lead to adverse, unintended consequences and have limited therapeutic modalities to reverse such changes. The purpose of this study was to apply the new FNIH definitions of sarcopenia, using low lean mass (LLM) as its primary definition, to a representative cohort of U.S. adults with and without obesity based on different fat indices. We then aimed to ascertain the impact of these classifications on long-term mortality. An exploratory analysis was performed to identify baseline predictors of overall mortality in these LLM with obesity groups with the anticipation that this may allow clinicians to better target individuals at highest risk.
Methods

Study Design and Sample
The National Health and Nutrition Examination Surveys (NHANES) are cross-sectional survey data conducted by the Centers for Disease Control and Prevention of individuals representative of the U.S. population. NHANES oversamples minorities and older adults and is a multistage, complex stratified, probability sampling design. All procedural manuals and survey contents are publically accessible and available online at http://www.cdc.gov/nchs/nhanes. Survey data from 1999 to 2004 were used for this analysis after being downloaded in September 2015. Mortality data were downloaded in February 2016. NHANES had its own formal institutional review board process. Our institution exempted this study due to the nature of the de-identified data. We included 4,984 subjects after restricting our sample to individuals aged 60 years and older with body composition measures (see below) from an initial study cohort of 38,077 screened subjects. Of the 31,125 interviewed, 29,402 were evaluated in a mobile examination center by a physician. Our rationale for limiting to age older than 60 was that the prevalence of sarcopenia and sarcopenic obesity is much less in younger populations (3).
Demographic Covariates
All sociodemographic variables (age, sex, race, poverty income ratio, smoking status) and comorbid medical conditions were assessed using a self-reported questionnaire. These questionnaires were completed by the subject or their caregiver if participants were unable to do so. Individuals were classified by age category (60-69.9, 70-79.9, and 80+ years) and race (non-Hispanic White, non-Hispanic Black, Hispanic, and Other). Poverty income ratio is an index for the ratio of family income to poverty based on the Department of Health and Human service poverty guidelines. It was calculated by dividing family income by poverty guidelines specific to family size, as well as the appropriate year and state. Smoking status was defined as never smokers, former smokers of cigarettes, or current smokers. Presence of kidney disease was defined in individuals based on a Modification of Diet in Renal Disease Study formula for glomerular filtration rate of less than 60 mL/min/m 2 (10).
Anthropometric Measures
All measurements were performed on the right side of the body to the nearest tenth of a centimeter except if amputations, casts, or other factors prevented an assessment. A stadiometer measured height after deep inhalation and an electronic digital scale, calibrated in kilograms, assessed weight. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Waist circumference (WC) was measured standing at the iliac crest (at the mid-axillary line) using a tape measure. Obesity based on BMI and WC were defined as greater than or equal to 30 kg/m 2 and greater than or equal to 88/102 cm in men and women (11) .
Measurement of LLM and Obesity
Dual-energy x-ray absorptiometry using a QDR-4500 Hologic scanner (Bedford, MA) provided all body composition variables of fat and appendicular lean mass (ALM) and their respective percentages. ALM was defined as the sum of the muscle mass of both arms and legs. For this assessment, NHANES excluded subjects whose height was above 192.5 cm or weight was above 136.4 kg. All metal objects were removed with the exception of false teeth and hearing aids. Each NHANES cycle consisted of similar operations procedures. The FNIH definition for sarcopenia was used to define LLM as an ALM below 19.75 kg and below 15.02 kg in men and women, respectively (1) . A second FNIH definition of a ratio of ALM:BMI below 0.789 and below 0.512, respectively, was also considered (see the Statistical Analysis section). Obesity using body fat was defined as in our previous studies of 25% or above in men and 35% or above in women (12) . LLM with obesity was defined as the combination of each definition of LLM with each respective definition of obesity.
Mortality Data
All mortality information was cross-linked to the NHANES datasets using National Death Index data. All data are publically available and contains de-identified death certificate data, updated through December 31, 2011. Death data were based upon a probabilistic match between NHANES and National Death Index data. Cause of death was classified as cardiovascular (including stroke) or other, following the International Statistical Classification of Disease, Injuries and Causes of Death guidelines with the 9th revision used for those dying in 1999, and the 10th revision for all others. Procedures are in place to harmonize the differences in definitions and causes of death. Time of follow-up was calculated in months from interview date to date of death or most recent vital record. Vital status was accounted for in more than 99% of our sample.
Statistical Analysis
A secondary analysis of the data was performed after merging all relevant files into a master file in February 2016. We followed standard NHANES analytic procedures for weighting, accounting for primary sampling unit, cluster, and strata. Continuous data were presented as means ± SE or counts (weight prevalence). Data are presented for the overall cohort and stratified by sex. A t test and chi-square compared continuous and categorical data, respectively, between survivors and decedents. A weighted prevalence of LLM using the ALM definition, obesity (using body fat), and LLM with obesity, using a combination of the LLM and obesity definition, was calculated. Rates were stratified by age group (60-69.9, 70-79.9, and ≥80 years). The primary analysis was the use of Cox's proportional hazard models to assess the association of all-cause and cardiovascular mortality risk with LLM and LLM with obesity in separate models. This analysis was then stratified by sex. Three separate proportional hazard models adjusting for a priori covariates were constructed: Model 1 was unadjusted, Model 2 adjusted for age, sex (where appropriate), race, education, and smoking status; Model 3 additionally adjusted for diabetes, congestive heart failure, non-skin cancer, coronary artery disease, arthritis, and physical activity. Proportional hazard assumptions were confirmed. An exploratory analysis determined predictors of overall mortality in those with LLM and LLM with obesity using stepwise selection methods. A p value of .10 was the upper level for removal from the model, and a value of .05 was the lower level for the addition to the model. Lastly, as FNIH considered two definitions of sarcopenia (ALM and ALM:BMI), we replicated the above analytic method using ALM:BMI in lieu of ALM, as a sensitivity analysis. All analyses were conducted using STATA v. 12 (College Station, TX). A p value of less than 0.05 was considered statistically significant.
Results
Of the 4,984 subjects, the mean age was 71.1 ± 0.19. Median follow-up time was 102 months (interquartile range: 78, 124). Table 1 presents data on the overall cohort, by sex, and the differences in sociodemographic characteristics by vital status. Table 2 highlights comorbidities and anthropometric characteristics of the cohort, by vital status. Generally, decedents had a higher comorbidity burden than those alive across both sexes. Table 3 presents data on the overall prevalence rates of LLM and LLM with obesity. Rates were lower in males than in females. Rates increased with age across both sexes and the definition of sarcopenic obesity using body fat resulted in the highest prevalence for both sexes (Figure 1a and b). The ALM:BMI rates are represented in Supplementary Appendix 1. Using BMI or WC as other obesity indices, rates of LLM with obesity were considerably lower (Supplementary Appendix 2) .
The survival analyses are presented in Table 4 for LLM. There were 1,901 deaths (35.0%) of which 521 (9.0%) were classified as cardiovascular. In the overall population, participants with LLM were at higher adjusted risk of death (hazard ratio Note: Data are mean ± SEs or counts (%). Data are weighted according to the National Health and Nutrition Examination Survey protocol. PIR = poverty income ratio. Note: Data are mean ± SEs or counts (%). Data are weighted according to the National Health and Nutrition Examination Survey protocol. ALM = appendicular lean mass; BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; WC = waist circumference. Blacks = Non-Hispanic Blacks; Hispanics = Hispanic American; Whites = Non-Hispanic Whites. Appendix 4) . Tables 5 and 6 and Supplementary Appendices 5 and 6 demonstrate the univariate and multivariate predictors of mortality in subjects meeting criteria for LLM or LLM with obesity. Consistently, multivariate predictors suggested that age, diabetes mellitus, non-Hispanic Black, poverty income ratio, history of non-skin cancer, and kidney disease were all predictive of death.
Discussion
We observed a higher risk of death in individuals with LLM using the ALM definition of sarcopenia particularly in men. The use of body fat as a measure for adiposity attenuated the mortality risk in those identified as having LLM with obesity. Cardiovascular mortality was higher in males than in females.
To our knowledge, only two studies have examined the impact of sarcopenia (or LLM) on long-term mortality (4,13) using the FNIH criteria. The initial FNIH study demonstrated inconsistent results of a pooled HR using ALM over a 10-year period of HR 1.37 (1.03, 1.82) in men and 1.07 (0.81, 1.41) in women. Hirani et al. (13) demonstrated a HR of 1.65 (1.30, 2.09) in those with low ALM alone on long-term mortality with a median follow-up of 7 years. Clinical weakness over low ALM is likely the predominant predictor of clinical outcomes and is that which factors in the trajectory of decline and is implicated in the mortality process.
Previous studies examining the relationship of sarcopenia with mortality used different defining characteristics of sarcopenia (14) .
A recent meta-analysis demonstrated that in 10 studies, there was an 81% higher risk of mortality (95% CI: 1.61, 2.18) in those fulfilling criteria of sarcopenia as compared to those in the non-sarcopenia group. This analysis had a limited follow-up time of 4.17 years and sampled fewer individuals (n = 3,797) than ours (15) . Sarcopenia has emerged as a predictor of death in cancer and renal disease populations (16-18) and we accounted for these confounding conditions by adjusting for them in our multivariable analysis. Our previous report using NHANES III assessed the relationship of LLM defined using bioelectrical impedance data (19) . However, rates of LLM and LLM with obesity were much lower than those observed in this current study which used dual-energy x-ray absorptiometry for assessment of body composition and women had higher mortality risks Note: Data are counts (prevalence rates), after weighting and accounting for strata and primary sampling units. ALM = appendicular lean mass; BF = body fat. Rates of low lean mass obesity using the ALM definitions of sarcopenia from the Foundation for the National Institutes of Health and three definitions of obesity (body fat percent, waist circumference, and body mass index). Obesity defined using body fat cutpoints were ≥25% in men and ≥35% in females; waist circumference ≥88/102 cm in men/women and body mass index ≥30 kg/m 2 . Sarcopenia is defined as ALM <19.75 kg and <15.02 kg in men and women. ALM = appendicular lean mass.
than that of men. Sex-specific biologic differences on time-dependent mortality are unclear as well as whether the duration of inflammation may potentially explain our results. A paucity of studies examine sarcopenia defined using LLM with obesity as a predictor for death. A meta-analysis demonstrated significant study heterogeneity with a marginally higher risk of all-cause mortality, based on earlier definitions of sarcopenia and obesity (HR 1.24 [1.12-1.37]), which was higher in males than females (20) . Our results do conflict with those observed by Atkins and Chuang that showed no relationship between cardiovascular mortality and sarcopenic obesity (21, 22) . However, these authors used WC and mathematical thresholds unique to their population to assess adiposity, which we have previously debated. By using body fat cutoffs for adiposity assessment rather than conventional anthropometric measures, we avoid the poor sensitivity these markers have in ascertaining adiposity (23) . This allows valid classification of individuals with obesity, which in conjunction with LLM, can assist in correctly categorizing individuals with LLM with obesity.
Our results suggest that body fat-defined obesity may indeed be protective in some individuals. Such older individuals may not be susceptible to obesity-related complications and may have survived, while others less resistant have died. Older cohorts are also at higher risk of competing mortality risks than younger cohorts. We also adjusted for a number of comorbidities known to negatively impact mortality which could partially explain these results. Another hypothesis is that late-life energy reserves may be protective; the interplay between adipose and skeletal muscle tissue on practical clinical outcomes requires future investigation. Our results suggest . ALM = appendicular lean mass; CAD = coronary artery disease; CHF = congestive heart failure; CI = confidence interval; COPD = chronic obstructive pulmonary disease; HR = hazard ratio; NHB = non-Hispanic black; NHW = non-Hispanic white; PIR = poverty income ratio.
that subjects with LLM with obesity may not necessarily be at higher risk of adverse events.
Our exploratory analysis provides some interesting insight into potential mortality predictors, irrespective of sarcopenia definition. Generally, age, diabetes, non-Hispanic Black race, cancer, and kidney diseases were strong predictors of death. We acknowledge that we limited this current analysis to those with LLM or LLM with obesity measurements at baseline. Our sample was also limited by the number of deaths in each group to allow us to perform such predictive analytics. These predictors are not surprising in that each of these disease entities, and age itself, strongly predict future death. While preliminary, these results suggest the importance of maintaining function and optimizing disease-specific risk in these aforementioned populations.
We recognize a number of limitations in our analysis. First, our data are dependent on self-reported measures. Second, we relied solely on body composition data and were unable to integrate muscle strength of functional data into our analysis. Third, results are only generalizable to the noninstitutionalized adults living in the United States not those residing in nursing homes who may have higher degrees of LLM or obesity. Fourth, our results use a fixed baseline data point with a long-term mortality endpoint. While helpful to characterize the longitudinal relationships, the analysis does not account for weight-cycling which is known to impact functional and mortality estimates.
Using a national representative cohort, our results suggest the importance of sarcopenia defined using the FNIH ALM definition, particularly in males, both in terms of overall and cardiovascular mortality. Our results suggest that the FNIH defined ALM:BMI can also be considered, but a harmonized definition is critically needed. Obesity defined using body fat may mitigate the risk of death from sarcopenia, suggesting the possibility of an obesity paradox. Our exploratory analysis demonstrates consistent mortality predictors in this population that are not otherwise surprising but should prompt clinicians to continue to focus on modalities to improve function and muscle mass in these individuals. Longitudinally designed studies with intermittent data points can account for variations in medical, physical, and social determinants of long-term health. Note: All values represent HRs with 95% CIs. Kidney disease was determined using the Modification of Diet in Renal Disease formula and classified if glomerular filtration rate was <60 mL/min/m 2 . ALM = appendicular lean mass; CHF = congestive heart failure; CI = confidence interval; HR = hazard ratio; PIR = poverty income ratio. Stepwise regression models integrating all of the above key variables. We present only predictors that were significant in the multivariate models A p value of .10 was the upper level for removal from the model, and a value of .05 was the lower level for the addition to the model.
